Loading...
Loading...
TRVN| Name | Value |
|---|---|
| Revenues | 283.0K |
| Cost of Revenue | 114.0K |
| Gross Profit | 169.0K |
| Operating Expense | 5,746.0K |
| Operating I/L | -5,577.0K |
| Other Income/Expense | 608.0K |
| Interest Income | 190.0K |
| Pretax | -4,969.0K |
| Income Tax Expense | -30.0K |
| Net Income/Loss | -4,939.0K |
Trevena, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative medicines for central nervous system disorders. The company's lead product candidates include OLINVYK (Oliceridine) injection for managing moderate-to-severe acute pain, TRV027 for treating acute lung injury and abnormal blood clotting in COVID-19 patients, TRV250 for acute migraine, TRV734 for moderate-to-severe acute and chronic pain, and TRV045 for chronic pain management. Trevena, Inc. generates revenue through the development and potential commercialization of these novel medicines, with a focus on addressing unmet medical needs in the central nervous system disorder space.
